Title of article
Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinsonʹs disease: an open label, phase I trial
Author/Authors
Michael G Kaplitt، نويسنده , , Andrew Feigin، نويسنده , , Chengke Tang، نويسنده , , Helen L Fitzsimons، نويسنده , , Paul Mattis، نويسنده , , Patricia A Lawlor، نويسنده , , Ross J Bland، نويسنده , , Deborah Young، نويسنده , , Kristin Strybing، نويسنده , , David Eidelberg، نويسنده , , Matthew J. During، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2008
Pages
9
From page
2097
To page
2105
Abstract
Summary
Background
Dopaminergic neuronal loss in Parkinsonʹs disease leads to changes in the circuitry of the basal ganglia, such as decreased inhibitory GABAergic input to the subthalamic nucleus. We aimed to measure the safety, tolerability, and potenti
Journal title
The Lancet
Serial Year
2008
Journal title
The Lancet
Record number
591516
Link To Document